Longitudinal in vivo biodistribution of nano and micro sized hydroxyapatite particles implanted in a bone defect
Y Liu, S Sebastian, J Huang, T Corbascio… - … in Bioengineering and …, 2022 - frontiersin.org
Hydroxyapatite (HA) has been widely used as a bone substitute and more recently as a
carrier for local delivery of bone targeted drugs. Majority of the approved HA based …
carrier for local delivery of bone targeted drugs. Majority of the approved HA based …
[HTML][HTML] Ibandronate sodium and zoledronate sodium in the treatment of senile osteoporosis: efficacy, impact on quality of life and cost-effectiveness analysis
S Liang, S Hu, H Guo, L Dong, G Liu… - American Journal of …, 2021 - ncbi.nlm.nih.gov
Objective: To investigate the efficacy of ibandronate sodium and zoledronate sodium in the
treatment of senile osteoporosis and their impact on quality of life, and to analyze the cost …
treatment of senile osteoporosis and their impact on quality of life, and to analyze the cost …
Comparison of the efficacy and renal safety of bisphosphonate between low-dose/high-frequency and high-dose/low-frequency regimens in a late-stage chronic …
R Fujita, M Ota, D Sato, D Nakazawa… - Calcified Tissue …, 2020 - Springer
The efficacy and renal safety of low-dose/high-frequency (LDHF) dosing and high-dose/low-
frequency (HDLF) dosing of bisphosphonates (BPs) are comparable in patients with normal …
frequency (HDLF) dosing of bisphosphonates (BPs) are comparable in patients with normal …
Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing
EA Swallow, MW Aref, CE Metzger, S Sacks… - Bone, 2019 - Elsevier
Background Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture
risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not …
risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not …
[HTML][HTML] Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease
EA Swallow, CE Metzger, NX Chen, JM Wallace… - Bone Reports, 2022 - Elsevier
Purpose Patients with chronic kidney disease (CKD) have high risk of fracture in part due to
cortical bone deterioration. The goal of this study was to assess the impact of two different …
cortical bone deterioration. The goal of this study was to assess the impact of two different …
Renal insufficiency and bone loss
SM Ott - Current Opinion in Rheumatology, 2019 - journals.lww.com
Renal insufficiency and bone loss : Current Opinion in Rheumatology Renal insufficiency and
bone loss : Current Opinion in Rheumatology Log in or Register Subscribe to journalSubscribe …
bone loss : Current Opinion in Rheumatology Log in or Register Subscribe to journalSubscribe …
Osteoporosis associated with chronic kidney disease
SM Ott, GJ Elder - Marcus and Feldman's Osteoporosis, 2021 - Elsevier
Chronic kidney disease (CKD) is associated with high rates of fracture, cardiovascular
events, and mortality. The pathophysiology is complex, including reduced levels of Klotho …
events, and mortality. The pathophysiology is complex, including reduced levels of Klotho …
[图书][B] Approaches to Improve the Structure and Function of the Skeleton in Chronic Kidney Disease
EA Swallow - 2022 - search.proquest.com
APPROACHES TO IMPROVE THE STRUCTURE AND FUNCTION OF THE SKELETON IN
CHRONIC KIDNEY DISEASE Elizabeth Anne Swallow Submitted to t Page 1 …
CHRONIC KIDNEY DISEASE Elizabeth Anne Swallow Submitted to t Page 1 …
[PDF][PDF] 進行期慢性腎臓病を伴う骨粗鬆症に対するビスフォスフォネート製剤の低用量高頻度投与と高用量低頻度投与の治療効果および安全性の比較検討
藤田諒 - 2021 - eprints.lib.hokudai.ac.jp
要旨 [背景と目的] 慢性腎臓病 (Chronic kidney disease; CKD) は慢性に経過するすべての腎臓
病を指し, 本邦でも患者数は 1330 万人にものぼる. また, 原発性骨粗鬆症も本邦では現在 1280 …
病を指し, 本邦でも患者数は 1330 万人にものぼる. また, 原発性骨粗鬆症も本邦では現在 1280 …